The effect of curcumin on the prevention of paclitaxel and platinum compounds-induced neuropathy in cancer patients

The effect of curcumin on the prevention of paclitaxel and platinum compounds-induced neuropathy in cancer patients: a randomized double-blinded controlled clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191106045356N6

Enrollment

Registered

2021-07-29

Start date

2021-05-22

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy induced neuropathy.

Interventions

Intervention 1: Intervention group: Daily recipient of 80 mg of oral curcumin from Sina Droo Pharmaceutical Company with Sina Curcumin brand for 28 days. Patients are evaluated for neuropathy on days

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Age 20-50 years Initiation of the treatment with paclitaxel and platinum compounds in cancer patients

Exclusion criteria

Exclusion criteria: History of allergy to curcumin or turmeric Having diseases that cause neuropathy such as diabetes or conditions such as alcoholism.

Design outcomes

Primary

Measure	Time frame
The neuropathy score is determined based on the Michigan Neuropathy Screening Instrument (MNSI) questionnaire, which includes a test with 20 yes / no questions. Timepoint: Days 1, 4, 7, 14, 28 science starting internention. Method of measurement: Patient examination and Michigan Neuropathy Screening Instrument (MNSI) questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohsen Zabihi

Yazd University of Medical Sciences

mzabihi100@gmail.com+98 35 3820 3419

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026